問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳友木

Recruiting

List

24Cases

2024-10-01 - 2034-06-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2025-03-01 - 2028-03-31

Phase I/II

Active
An open-label, multi-group, phase 1b/2 trial evaluating the safety, efficacy, and optimal dose of Telisotuzumab Adizutecan in combination with a PD-1 immune checkpoint inhibitor in treatment-naïve patients with untreatable genetic mutations in advanced or metastatic non-squamous non-small cell lung cancer (AndroMETa-Lung-536).

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
9Sites

Recruiting9Sites

2022-05-01 - 2026-03-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-11-01 - 2031-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-11-01 - 2027-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2032-01-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2026-06-01 - 2028-06-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-08-31 - 2032-02-12

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2024-11-01 - 2027-04-30

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB